Brad Canino
Stock Analyst at Guggenheim
(4.69)
# 150
Out of 5,090 analysts
22
Total ratings
72.22%
Success rate
23.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.68 | - | 2 | Dec 4, 2025 | |
| GLTO Galecto | Initiates: Buy | $32 | $22.60 | +41.59% | 1 | Dec 1, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $107.15 | +44.66% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $4.41 | +58.73% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $66.84 | +34.65% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $18.91 | +111.53% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $45.50 | +97.80% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $27.54 | -27.38% | 1 | Oct 8, 2025 | |
| CELC Celcuity | Initiates: Buy | $110 | $106.56 | +3.23% | 1 | Sep 22, 2025 | |
| ORIC ORIC Pharmaceuticals | Assumes: Buy | $18 | $11.83 | +52.16% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $15 | $8.02 | +87.03% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.62 | +205.93% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $16.34 | +340.64% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $12.00 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $450 | $27.42 | +1,541.14% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $26.30 | +109.13% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $44.18 | -32.10% | 2 | Mar 31, 2021 |
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.68
Upside: -
Galecto
Dec 1, 2025
Initiates: Buy
Price Target: $32
Current: $22.60
Upside: +41.59%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $107.15
Upside: +44.66%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $4.41
Upside: +58.73%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $66.84
Upside: +34.65%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $18.91
Upside: +111.53%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $45.50
Upside: +97.80%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $27.54
Upside: -27.38%
Celcuity
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $106.56
Upside: +3.23%
ORIC Pharmaceuticals
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $11.83
Upside: +52.16%
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $8.02
Upside: +87.03%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.62
Upside: +205.93%
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $16.34
Upside: +340.64%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $12.00
Upside: -
Mar 31, 2021
Initiates: Neutral
Price Target: $450
Current: $27.42
Upside: +1,541.14%
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $26.30
Upside: +109.13%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $44.18
Upside: -32.10%